Introduction
============

Chronic obstructive pulmonary disease (COPD) is associated with a progressive decline in lung function and resultant chronic respiratory failure. This leads to significant rates of hospitalization, disability, and death.[@b1-copd-8-581] COPD is also associated with sleep-disordered breathing and nocturnal hypoventilation, resulting in nocturnal and daytime hypoxemia and hypercapnia.[@b2-copd-8-581],[@b3-copd-8-581] These, in turn, can contribute to fatigue, dyspnea, and impaired quality of life. Nocturnal noninvasive positive pressure ventilation (NPPV) can theoretically rest overloaded respiratory muscles, prevent nocturnal hypoventilation, and reset central respiratory drive in patients with hypercapnia. The use of NPPV in late-stage COPD appears logical to change this inexorable course, to alleviate symptoms, and to improve quality of life. While NPPV has a definite role in the management of acute hypercapnic respiratory failure,[@b4-copd-8-581] its role in the management of late-stage stable COPD is controversial. Multiple studies have shown no survival benefit for nocturnal NPPV in chronic stable hypercapnic COPD patients.[@b5-copd-8-581]--[@b10-copd-8-581] The effects on quality of life and dyspnea scores in such patients have been inconsistent.[@b8-copd-8-581]--[@b11-copd-8-581] The variable efficacy might have been due to late administration of the intervention in the course of disease, in the presence of advanced hypercapnic respiratory failure. We sought to assess the effect of applying NPPV on indices of health-related quality of life in patients with relative normocapnia. We hypothesized that patients with stable severe COPD and partial pressure of carbon dioxide (PaCO~2~) \<52 mmHg have improved quality of life and reduced dyspnea with the use of NPPV.

Materials and methods
=====================

We conducted a prospective, randomized controlled study.[@b12-copd-8-581] Subjects were screened from the pulmonary clinic at the University of Iowa Hospital. The protocol was approved by the institutional review board (20010044) and informed consent was obtained from each subject.

Patients
--------

Subjects with stable COPD, defined as a forced expiratory volume in the first second (FEV~1~)/forced vital capacity (FVC) ratio of \<0.70, with at least a 10 pack-year smoking history and PaCO~2~ \<52 mmHg were eligible.[@b13-copd-8-581] Stable COPD was defined as no exacerbations in the 4 weeks prior to initiation of the study. Only patients with a low clinical probability of having obstructive sleep apnea as assessed using the Berlin Questionnaire were included. This was done to remove the possible confounding effect of sleep apnea.[@b14-copd-8-581] Those with diagnoses of congestive heart failure, obstructive sleep apnea, chronic respiratory conditions other than COPD, age \<35 years, any disease limiting life expectancy to less than 2 years, active malignancy other than nonmelanotic skin cancer in the previous 2 years, and with any anatomic variation or disease process that precluded wearing a nasal mask were excluded. Subjects could be active or ex smokers, but had to have a stable smoking status for at least 6 months prior to study initiation. Patients could also have undergone pulmonary rehabilitation or be in a maintenance program, but they could not initiate a pulmonary rehabilitation program during the 6-month observation period.

Subjects were randomized to receive or not receive domiciliary NPPV at 15/5 cm H~2~O. Subjects were randomized in a 1:1 ratio to receive NPPV versus control treatment using a random number generator. Randomization was done using opaque sealed envelopes which were opened during screening visits. For this study, we defined hypercapnia as ≥52 mmHg based on the criteria used for reimbursement for noninvasive ventilation by the Centers for Medicare and Medicaid Services.[@b15-copd-8-581] Once subjects were randomized to the NPPV arm, they were initiated on NPPV at home by a respiratory therapist. Subjects were fitted with a nasal-oral contour comfort gel full face mask (Respironics Inc, Murrysville, PA, USA) or nasal pillows (Nellcor Puritan-Bennett Inc, Pleasanton, CA, USA) as needed for optimal comfort and minimal leak. NPPV was initiated at home using a BiPAP® Synchrony ventilator (Respironics Inc) and titrated to final pressures of 15/5 cm H~2~O within a week. Subjects were instructed to use the ventilator all night or for at least 6 hours every night for the next 6 months. Respiratory therapists called the subjects every day during the first week to ensure optimal usage and to troubleshoot any complications. The therapists also made a home visit to check the use of domiciliary NPPV periodically during the first week and as needed thereafter. All subjects were provided with heated humidification.

A complete history and physical examination was undertaken, with a posterolateral chest radiograph, 12-lead electrocardiogram, lung physiology (spirometry, arterial blood gases on room air), and respiratory muscle strength (negative inspiratory force \[NIF\]) at baseline. We measured exercise capacity by the six-minute walk test.[@b16-copd-8-581] Dyspnea was assessed using the Baseline Dyspnea Index and the Transitional Dyspnea Index (TDI).[@b17-copd-8-581] We included a global assessment of health-related quality of life developed for patients with chronic lung disease, ie, the Chronic Respiratory Disease Questionnaire (CRQ).[@b18-copd-8-581] Sleep quality was assessed using the Pittsburgh Sleep Quality Index.[@b19-copd-8-581] Subjects were reassessed at 6 weeks, 3 months, and 6 months after randomization. The primary outcome was change in the CRQ domains and change in TDI. The minimal clinically important difference in CRQ was defined as a change in the score by 0.5 units,[@b18-copd-8-581] and that in TDI by one unit.[@b17-copd-8-581] Secondary outcomes were change in NIF, arterial partial pressure of oxygen (PaO~2~), FEV~1~, and six-minute walk test. Ventilator use data were downloaded using Encore software (Respironics Inc) at each follow-up visit.

Side effects and compliance
---------------------------

At each visit, subjects on NPPV were asked about side effects, such as dryness of eyes, sinus congestion, skin abrasions, and epistaxis. Compliance was assessed by both patient-reported hours of use at each visit and machine-downloaded data for hours of use. Data obtained from the machine were used for analyses.

Statistical analysis
--------------------

Results are expressed as the mean (standard deviation) for normally distributed data and median with interquartile range for nonuniformly distributed data. The baseline characteristics of subjects in the NPPV and control arms were compared using the Student's *t*-test for continuous variables and the Mann--Whitney *U* test as appropriate, and the chi-square test for categorical variables. Differences within groups at the end of 6 months were compared with baseline using the paired *t*-test and between groups using the independent *t*-test. Repeated-measures analysis of variance was used to assess significant changes over time, and the independent *t*-test was used to assess where any change occurred between groups.

Distribution of data was assessed using Mauchly's test of sphericity, and Greenhouse-Geisser correction was used where sphericity could not be assumed. Relationships between outcomes and change from baseline to 6 months in variables that could affect outcomes were assessed using Spearman's correlation. A *P*-value\<0.05 was considered to be statistically significant. Multivariate analyses for outcomes after adjusting for baseline PaCO~2~ and NIF were done and showed no change in the results, and hence are not reported. We did not make any sample size justification because this was a pilot study in relatively normocapnic subjects. All analyses were performed using Statistical Package for the Social Sciences version 11.5 software (SPSS Inc., Chicago, IL, USA).

Results
=======

Thirty subjects with COPD were recruited. Twenty-seven completed all assessments, ie, 15 in the NPPV group and 12 in the control group ([Figure 1](#f1-copd-8-581){ref-type="fig"}). The baseline characteristics of subjects who were able to complete the study are shown in [Table 1](#t1-copd-8-581){ref-type="table"}. There were a higher proportion of males in the control group. The two groups were well matched for age, body mass index, disease severity, and baseline indices of dyspnea, functional capacity, quality of life, and sleep indices. At 6 weeks and 3 months, NPPV resulted in a significant improvement in TDI in the NPPV arm (data in [Figure 2](#f2-copd-8-581){ref-type="fig"}, [Table S1](#SD1-copd-8-581){ref-type="supplementary-material"}). However, this effect persisted only in the TDI-Task at 6 months (−0.8 versus −1.8, *P*=0.03). [Table 2](#t2-copd-8-581){ref-type="table"} shows the effects of NPPV at the end of 6 months. NPPV did not result in improvement in global quality of life as assessed by the total CRQ score. Subjects using NPPV did experience a small improvement in the mastery domain of the CRQ, a difference in the realm of being clinically significant (0.6 versus −0.1, *P*=0.04, [Figure 2](#f2-copd-8-581){ref-type="fig"}). When assessed by repeated measures over time, only the improvement in the mastery domain of CRQ was sustained (data in [Table S1](#SD1-copd-8-581){ref-type="supplementary-material"}).

The oxygenation status of controls worsened over the period of the study (−7.2 mmHg), whereas NPPV resulted in conservation of oxygen levels (+2.1 mmHg, *P*=0.02). There was a trend towards improvement in NIF (delta 7 with NPPV versus delta 0.3 in controls), but this did not reach statistical significance (*P*=0.14). There was no change in PaCO~2~. There was also no improvement in six-minute walk distance. NPPV did not result in a change in FEV~1~. There was no difference in the number of exacerbations in either group during the period of the study, with one exacerbation in each group.

Compliance and side effects
---------------------------

The average duration of NPPV use per night was about 3.1 hours ([Table 3](#t3-copd-8-581){ref-type="table"}). More than 40% used it for more than 4 hours per night. More than half (8/15) used it for more than 4 hours in the first week (initial adopters). Of those using NPPV for more than 4 hours per night in the first week, 75% used NPPV for a mean of more than 4 hours per night for the entirety of the study. Eighty-eight percent of initial adopters expressed interest in continuing use of NPPV beyond the duration of the study. Even though there were some adverse effects from using NPPV, these were minimal ([Table 4](#t4-copd-8-581){ref-type="table"}). There was no change in the quality of sleep ([Table 2](#t2-copd-8-581){ref-type="table"}). Overall, 53% of subjects indicated a willingness to continue using NPPV beyond the period of the study. Interestingly, the improvement in CRQ-Mastery correlated significantly with the average number of hours of NPPV use (Spearman's *r*=−0.83, *P*\<0.001, [Figure 3](#f3-copd-8-581){ref-type="fig"}). More side effects were reported by subjects in the NPPV arm, although this did not preclude them from continued use of the intervention ([Table 4](#t4-copd-8-581){ref-type="table"}).

Discussion
==========

We showed that there was a small improvement in some quality of life indices in patients with stable COPD administered NPPV for 6 months. There was a significant improvement in CRQ-Mastery and TDI-Task over time with application of NPPV. There was also a beneficial effect on PaO~2~.

The role of domiciliary nocturnal NPPV in the management of chronic stable COPD is controversial. The current literature is conflicting, but seems to favor its use in patients with hypercapnia, and with high intensity, targeting lowering PaCO~2~ levels. While multiple retrospective observational studies have shown a survival benefit for nocturnal NPPV in chronic stable hypercapnic COPD patients,[@b5-copd-8-581]--[@b7-copd-8-581],[@b20-copd-8-581] these results have not been supported in randomized controlled trials.[@b8-copd-8-581]--[@b10-copd-8-581] These, and other smaller studies, also found inconsistent effects on sleep quality, quality of life, and dyspnea scores in hypercapnic COPD patients using NPPV.[@b8-copd-8-581]--[@b11-copd-8-581],[@b21-copd-8-581]--[@b23-copd-8-581] Most of these trials attempted to use varying intensity of NPPV to reduce daytime hypercapnia and improve gas exchange, and seemed to indicate that adequate lowering of PaCO~2~ and nocturnal hypoventilation was associated with the most benefits.[@b24-copd-8-581] It is possible that the inconsistent effects of NPPV were due to usage of low levels of pressure. Dreher et al showed in a short-duration study that high-intensity NPPV with controlled pressure can significantly reduce nocturnal PaCO~2~, improve dyspnea scores, lung function tests, and quality of life.[@b25-copd-8-581] Based on these, Medicare and Medicaid Services recommended a cutoff of ≥52 mmHg, in addition to other criteria, for initiating domiciliary nocturnal NPPV in stable hypercapnic patients.[@b15-copd-8-581] In contrast with these recommendations, we hypothesized that the inconsistent effects seen in previous studies might have been due to the intervention being late in the course of disease.

In patients without hypercapnia, NPPV cannot be targeted toward PaCO~2~, but might still benefit patients by lowering the work of breathing. Although ours is the first study to target this group specifically, other studies did include subjects who had similar PaCO~2~ levels ([Table 5](#t5-copd-8-581){ref-type="table"}). To our knowledge, no study has compared the effect of NPPV in normocapnic COPD with controls not undergoing another intervention such as rehabilitation and domiciliary oxygen that could confound the results.

NPPV use was associated with some minor benefits in our study in the domain of mastery, and in preservation of PaO~2~. This supports the results seen in two other short-duration studies aiming to recruit hypercapnic patients, but with PaCO~2~ levels comparable with our inclusion criteria.[@b21-copd-8-581],[@b23-copd-8-581] The difference in oxygenation levels was a surprising finding, and is most likely due to NPPV leading to redistribution of airflow toward areas of better perfusion, resulting in improvement in ventilation/perfusion matching.[@b26-copd-8-581] Results from short-duration trials cannot be generalized because there can be a significant placebo effect from the mask,[@b27-copd-8-581] and there can also be significant problems with long-term compliance.[@b28-copd-8-581] A longer-duration randomized study by Casanova et al did not have PaCO~2~ level as an inclusion criterion but had a mean PaCO~2~ of 50.7 mmHg. In this study, there was a marginal improvement in Borg dyspnea score and in psychomotor coordination.[@b8-copd-8-581] Only the study by Garrod et al had PaCO~2~ levels comparable with those seen in our study. While they did show an improvement in exercise capacity, oxygenation, and CRQ, the study compared the effect of adding NPPV to an exercise program with exercise alone.[@b11-copd-8-581] We showed a change in some quality of life indices, but these were limited by the small number of subjects. In addition to baseline PaCO~2~ and improvement in hypoventilation, the other major factor that can affect study results is the intensity of NPPV used. Both these comparable randomized controlled studies used inspiratory and expiratory pressures similar to those used in the current study.[@b8-copd-8-581],[@b11-copd-8-581]

Our study has a number of strengths. We studied a group of patients who were not significantly hypercapnic, which is the usual target group for this intervention. We excluded patients with sleep apnea because improvement in sleep can potentially result in improvement in quality of life scores, independent of COPD-related improvement. We meticulously assessed side effects resulting from use of the NPPV mask. There were also some limitations to our study. We did not have a sham arm, and some of the results could be due to a placebo effect. The control subjects were all male, and while we are not aware of any gender differences in response to NPPV, this may have played a role. This study was underpowered to assess end points such as mortality or exacerbation frequency. However, those were not the main aims of our study. Compliance was low, probably due to lack of titration of pressures to each subject, lack of a run-in period, and the nature of the intervention. However, this is not unique to our study.[@b11-copd-8-581]

In conclusion, use of NPPV is associated with minor improvements in PaO~2~ and the subdomains of quality of life and dyspnea indices. Whether attainment of the minimal clinically important difference of 0.5 for the mastery domain is worth the cost and inconvenience of NPPV can only be determined by each patient based on cost and tolerance. Nevertheless, this study found a significant difference in this domain. Based on this small study, NPPV has some benefit in COPD patients with PaCO~2~ \<52 mmHg. Better compliance may be associated with improved outcome benefits in this group. Future large studies or meta-analyses in this group will clarify the utility of this intervention.

Supplementary material
======================

###### 

Comparison between groups at each time point and over all time points (repeated-measures analysis of variance)

                                                        Baseline       6 weeks        3 months                                                  6 months     *P*-value                                                                                                                                    
  ----------------------------------------------------- -------------- -------------- --------------------------------------------------------- ------------ ------------------------------------------------------- -------------- ------------------------------------------------------- ------------- -------
  FEV~1~ %pred                                          30.3 (7)       29.6 (7.4)                                                                            32.2 (11.8)                                             31.5 (6.4)     31.2 (11.9)                                             31 (7.8)      0.81
  FVC %pred                                             68.8 (14.1)    59.4 (8)                                                                              74.2 (19.2)                                             62.8 (8.8)     71.9 (16.7)                                             60.8 (30.2)   0.97
  NIF (cm H~2~O)                                        −48.9 (14.5)   −63.2 (23.9)                                                                          −59.7 (24.1)                                            −64.5 (23.9)   −55.9 (20.3)                                            −63 (21.9)    0.16
  PaCO~2~ (mmHg)                                        42.4 (5.6)     41.9 (4.6)                                                                            44.1 (7)                                                42.7 (4)       44.3 (8.5)                                              42.9 (4.5)    0.92
  PaO~2~ (mmHg)                                         65.1 (13.3)    73.9 (9.9)                                                                            62.1 (15.2)                                             66.7 (10.5)    67.2 (14.4)                                             66.8 (9.9)    0.12
  6MWD (m)                                              284 (101)      321 (91)       312 (110)                                                 320 (94)     295 (101)                                               335 (90)       280 (142)                                               304 (129)     0.50
  **CRQ score**                                                                                                                                                                                                                                                                                           
  Dyspnea                                               3.8 (1)        3.7 (1)        4.1 (0.9)                                                 3.7 (1.4)    3.9 (0.8)                                               3.6 (1.3)      4.1 (1.2)                                               3.4 (0.9)     0.64
  Fatigue                                               4.3 (1)        4.1 (1)        4.5 (0.9)                                                 3.9 (1.2)    4.4 (1)                                                 4.1 (1.1)      4.6 (1.3)                                               4.2 (0.9)     0.39
  Emotional function                                    5.5 (0.7)      5.3 (1.1)      5.6 (0.7)                                                 5.1 (1.1)    5.5 (0.9)                                               5.2 (1.3)      5.6 (1.1)                                               5.3 (1.3)     0.37
  Mastery[\*](#tfn12-copd-8-581){ref-type="table-fn"}   5 (1.1)        5.3 (1.4)      5.5 (1)                                                   5 (1.6)      5.6 (1)                                                 5.2 (1.2)      5.6 (1)                                                 5.2 (1.2)     0.047
  **Dyspnea**                                                                                                                                                                                                                                                                                             
  TDI-Function                                          1.9 (0.7)      1.5 (0.7)      0.6 (0.9)[\*](#tfn12-copd-8-581){ref-type="table-fn"}     −0.3 (1.1)   0.4 (0.8)[\*](#tfn12-copd-8-581){ref-type="table-fn"}   −0.2 (0.4)     0 (0.8)                                                 −0.2 (0.7)    0.31
  TDI-Task                                              1.3 (0.5)      1.4 (0.7)      0.3 (0.5)                                                 −0.3 (0.6)   0.4 (0.5)[\*](#tfn12-copd-8-581){ref-type="table-fn"}   −0.3 (0.9)     0.5 (0.7)[\*](#tfn12-copd-8-581){ref-type="table-fn"}   −0.3 (0.7)    0.07
  TDI-Effort                                            1.3 (0.5)      1.3 (0.5)      0.3 (0.5)[\*](#tfn12-copd-8-581){ref-type="table-fn"}     −0.3 (0.6)   0.4 (0.5)[\*](#tfn12-copd-8-581){ref-type="table-fn"}   −0.1 (0.7)     0.5 (0.7)[\*](#tfn12-copd-8-581){ref-type="table-fn"}   −0.3 (0.7)    0.13
  TDI total                                             4.5 (1.6)      4.2 (1.5)      1.3 (1.9)[\*\*](#tfn13-copd-8-581){ref-type="table-fn"}   −0.8 (1.9)   1.3 (1.7)[\*](#tfn12-copd-8-581){ref-type="table-fn"}   −0.3 (0.9)     0.9 (2)                                                 −0.5 (2.3)    0.28

**Notes:** All results expressed as the mean (standard deviation).

*P*\<0.05 and

*P*\<0.01.

**Abbreviations:** FEV~1~, forced expiratory volume in the first second; %pred, percent predicted; FVC, forced vital capacity; NIF, negative inspiratory force; NPPV, noninvasive positive pressure ventilation; PaCO~2~, partial pressure of carbon dioxide in arterial blood; PaO~2~, partial pressure of oxygen in arterial blood; 6MWD, six-minute walk distance; CRQ, Chronic respiratory Disease Questionnaire; TDI, Transitional Dyspnea Index at baseline.
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![Randomization and follow-up of patients in intervention and control arms.\
**Abbreviations:** COPD, chronic obstructive pulmonary disease; FEV~1~, forced expiratory volume in the first second; FVC, forced vital capacity; PaCO~2~, partial pressure of carbon dioxide in arterial blood; NPPV, noninvasive positive pressure ventilation.](copd-8-581Fig1){#f1-copd-8-581}

![Change in dyspnea measured by TDI and quality of life (CRQ-Mastery domain) over time in intervention and control arms. Dots represent control arm; squares represent intervention arm.\
**Notes:** \**P*\<0.05 and \*\**P*\<0.01.\
**Abbreviations:** TDI, Transitional Dyspnea Index; CRQ, Chronic Respiratory Disease Questionnaire; NPPV, noninvasive positive pressure ventilation.](copd-8-581Fig2){#f2-copd-8-581}

![Correlation between change in CRQ-Mastery domain and average numbers of hours of use of noninvasive positive pressure ventilation.\
**Abbreviation:** CRQ, Chronic Respiratory Disease Questionnaire.](copd-8-581Fig3){#f3-copd-8-581}

###### 

Comparison of baseline characteristics in cases and controls

  Variable                NPPV (n=15)    Controls (n=12)
  ----------------------- -------------- -----------------------------------------------------
  Age (years)^†^          70 (66--73)    68 (65--78)
  Sex (% male)            8 (53)         12 (100)[\*](#tfn2-copd-8-581){ref-type="table-fn"}
  BMI (kg/m^2^)           24.8 (2.8)     24.8 (4.8)
  Pack-years of smoking   59 (29)        61 (30)
  FEV~1~ %pred            30.3 (7)       29.6 (7.4)
  FVC %pred               68.8 (14.1)    59.4 (8)
  NIF (cm H~2~O)          −48.9 (14.5)   −63.2 (23.9)
  PaCO~2~ (mmHg)          42.4 (5.6)     41.9 (4.6)
  PaO~2~ (mmHg)           65.1 (13.3)    73.9 (9.9)
  6MWD (m)                284 (101)      321 (91)
  **CRQ score**                          
  Dyspnea                 3.8 (1)        3.7 (1)
  Fatigue                 4.3 (1)        4.1 (1)
  Emotional function      5.5 (0.7)      5.3 (1.1)
  Mastery                 5 (1.1)        5.3 (1.4)
  **Dyspnea**                            
  TDI-Function            1.9 (0.7)      1.5 (0.7)
  TDI-Task                1.3 (0.5)      1.4 (0.7)
  TDI-Effort              1.3 (0.5)      1.3 (0.5)
  TDI total               4.5 (1.6)      4.2 (1.5)
  PSQI                    3.7 (3)        6.1 (3.2)

**Notes:** All results are expressed as the mean (standard deviation) except for ^†^median (interquartile range).

*P*\<0.05.

**Abbreviations:** FEV~1~, forced expiratory volume in the first second; %pred, percent predicted; FVC, forced vital capacity; NIF, negative inspiratory force; NPPV, noninvasive positive pressure ventilation; PaCO~2~, partial pressure of carbon dioxide in arterial blood; PaO~2~, partial pressure of oxygen in arterial blood; 6MWD, six-minute walk distance; CRQ, Chronic Respiratory Disease Questionnaire; TDI, Transitional Dyspnea Index at baseline; PSQI, Pittsburgh Sleep Quality Index; BMI, body mass index.

###### 

Comparison of outcomes between intervention and control arms at 6 months

                                                             NPPV (n=15)    Controls (n=12)   *P*-value                                       
  ---------------------------------------------------------- -------------- ----------------- ----------- -------------- ------------- ------ ------
  FEV~1~ %pred                                               30.3 (7)       31.2 (11.9)       0.9         29.6 (7.4)     31 (7.8)      1.4    0.84
  FVC %pred                                                  68.8 (14.1)    71.9 (16.7)       3.1         59.4 (8)       60.8 (30.2)   1.3    0.74
  NIF (cm H~2~O)                                             −48.9 (14.5)   −55.9 (20.3)      7           −63.2 (23.9)   −63 (21.9)    0.3    0.14
  PaCO~2~ (mmHg)                                             42.4 (5.6)     44.3 (8.5)        1.9         41.9 (4.6)     42.9 (4.5)    1      0.68
  PaO~2~ (mmHg)[\*](#tfn5-copd-8-581){ref-type="table-fn"}   65.1 (13.3)    67.2 (14.4)       2.1         73.9 (9.9)     66.8 (9.9)    −7.2   0.02
  6MWD (m)                                                   284 (101)      280 (142)         −14         321 (91)       304 (129)     −17    0.73
  **CRQ score**                                                                                                                               
  Dyspnea                                                    3.8 (1)        4.1 (1.2)         0.3         3.7 (1)        3.4 (0.9)     −0.3   0.26
  Fatigue                                                    4.3 (1)        4.6 (1.3)         0.4         4.1 (1)        4.2 (0.9)     0      0.36
  Emotional function                                         5.5 (0.7)      5.6 (1.1)         0.2         5.3 (1.1)      5.3 (1.3)     0      0.46
  Mastery[\*](#tfn5-copd-8-581){ref-type="table-fn"}         5 (1.1)        5.6 (1)           0.6         5.3 (1.4)      5.2 (1.2)     −0.1   0.04
  **Dyspnea**                                                                                                                                 
  TDI-Function                                               1.9 (0.7)      0 (0.8)           −1.9        1.5 (0.7)      −0.2 (0.7)    −1.7   0.63
  TDI-Task[\*](#tfn5-copd-8-581){ref-type="table-fn"}        1.3 (0.5)      0.5 (0.7)         −0.8        1.4 (0.7)      −0.3 (0.7)    −1.8   0.03
  TDI-Effort                                                 1.3 (0.5)      0.5 (0.7)         −0.8        1.3 (0.5)      −0.3 (0.7)    −1.6   0.06
  TDI total                                                  4.5 (1.6)      0.9 (2)           −3.4        4.2 (1.5)      −0.5 (2.3)    −4.7   0.35
  PSQI                                                       3.7 (3)        3.4 (2.3)         0.2         6.1 (3.3)      5.7 (3.2)     0.4    0.77

**Notes:** All results are expressed as the mean (standard deviation).

*P*\<0.05.

**Abbreviations:** FEV~1~, forced expiratory volume in the first second; %pred, percent predicted; FVC, forced vital capacity; NIF, negative inspiratory force; PaCO~2~, partial pressure of carbon dioxide in arterial blood; PaO~2~, partial pressure of oxygen in arterial blood; 6MWD, six-minute walk distance; CRQ, Chronic Respiratory disease Questionnaire; TDI, Transitional Dyspnea Index at baseline; PSQI, Pittsburgh Sleep Quality Index.

###### 

Compliance with noninvasive positive pressure ventilation

  ------------------------------------------------------------ -------------
  Days used                                                    80.6 (69.1)
  \% days used                                                 42 (36)
  Number of hours used (average per night), patient-reported   3.9 (3.4)
  Number of hours used (average per night), machine-reported   3.1 (3.3)
  \% use greater than 4 hours per night                        40%
  Initial compliance (usage \>4 hours/night in first week)     8 (53%)
  Number indicating willingness to continue using device (%)   8 (53)
  ------------------------------------------------------------ -------------

**Note:** All numbers are expressed as the mean (standard deviation).

###### 

Side effects

                     NPPV (n=15)   Controls (n=12)
  ------------------ ------------- -----------------
  Dryness of eyes    1 (1)         1 (0)
  Sinus congestion   5 (2)         0
  Nose bleeds        1 (0)         1 (0)
  Discomfort         5 (3)         0
  Skin breaks        1 (1)         0

**Notes:** All numbers expressed as total number experiencing symptoms any time during course of study; numbers in brackets indicate those who had persistent symptoms at 6 months.

**Abbreviation:** NPPV, noninvasive positive pressure ventilation.

###### 

Comparison of randomized studies of domiciliary NPPV in chronic stable COPD without hypercapnea

                                                             n                              Duration of follow-up   NPPV intensity (cm H~2~O)   PaCO~2~ (mmHg)   Quality of life                           Dyspnea               Sleep            Exacerbations   Survival
  ---------------------------------------------------------- ------------------------------ ----------------------- --------------------------- ---------------- ----------------------------------------- --------------------- ---------------- --------------- ----------
  Garrod et al[@b11-copd-8-581] (versus rehabilitation)      Cases (n=23) Controls (n=22)   8 weeks                 16/4                        44.2             CRQ improved                              CRQ dyspnea = NS      --               --              --
  Casanova et al[@b8-copd-8-581] (versus domiciliary O~2~)   20 (24)                        One year                12/4                        50.7             Improvement in psychomotor coordination   Borg score improved   --               NS              NS
  Lin et al[@b23-copd-8-581]                                 12 (crossover)                 2 weeks                 12/--                       50.5             --                                        --                    Sleep worsened   --              --
  Strumpf et al[@b21-copd-8-581]                             7 (crossover)                  3 months                15/--                       50               --                                        NS                    NS               --              --
  Current study                                              15 (12)                        6 months                15/5                        42               CRQ-Mastery improved                      TDI-Task improved     NS               NS              --

**Abbreviations:** COPD, chronic obstructive pulmonary disease; NPPV, noninvasive positive pressure ventilation; PaCO~2~, partial pressure of carbon dioxide in arterial blood; CRQ, Chronic Respiratory Disease Questionnaire; O~2~, oxygen; TDI, Transitional Dyspnea Index; NS, no significant change.
